{
  "id": "biomarker-compliance",
  "display_name": "Biomarker Testing Compliance",
  "cohort": "Solid Tumors (NSCLC, mCRC, Breast) 2024-2025",
  "insight_type": "Testing Compliance",
  "summary": "Biomarker testing completion rate is 68%, 17% below benchmark. Improving compliance could yield $235,000/year.",
  "chart": {
    "type": "bar",
    "unit": "cancer_type",
    "data": [
      { "name": "NSCLC", "value": 78, "gap": -7, "highlight": false },
      { "name": "mCRC", "value": 65, "gap": -20, "highlight": true },
      { "name": "Breast", "value": 72, "gap": -13, "highlight": false },
      { "name": "Overall", "value": 68, "gap": -17, "highlight": true }
    ],
    "benchmark": 85,
    "nccn_target": 85
  },
  "financial_impact": {
    "annual_opportunity": "$235,000/year",
    "math": "$235,000/year = 47 patients Ã— $5,000 avg. revenue per appropriate therapy"
  },
  "clinical_impact": {
    "description": "Biomarker testing leads to appropriate targeted therapy selection, improving outcomes and quality of life.",
    "metrics": [
      {
        "type": "OS",
        "value": "+4.5 months",
        "description": "Median overall survival benefit with appropriate targeted therapy"
      },
      {
        "type": "PFS",
        "value": "+3.2 months",
        "description": "Median progression-free survival benefit"
      },
      {
        "type": "QoL",
        "value": "+15%",
        "description": "Enhanced quality of life measures"
      },
      {
        "type": "Hosp",
        "value": "-25%",
        "description": "Reduced hospitalization rate"
      }
    ],
    "quantitative": "85% guideline adherence target"
  },
  "action_steps": [
    {
      "text": "Implement reflex testing protocols for pathology",
      "icon": "document"
    },
    {
      "text": "Create biomarker testing order sets in EMR",
      "icon": "computer"
    },
    {
      "text": "Develop provider alert for untested eligible patients",
      "icon": "alert"
    },
    {
      "text": "Schedule biomarker testing workflow review",
      "icon": "users"
    }
  ],
  "suggestions": [
    "Review tissue collection protocols to ensure adequate specimen quality",
    "Consider liquid biopsy option for patients with insufficient tissue",
    "Implement biomarker testing patient education materials",
    "Evaluate turnaround time for critical biomarker results"
  ],
  "drilldowns": [
    {
      "label": "View by Payer Type",
      "cohort": "Solid Tumors, by Payer Type",
      "jsonFile": "biomarker-compliance-by-payer.json",
      "drilldownLevel": 1
    },
    {
      "label": "Compare Sites",
      "cohort": "Solid Tumors, by Site",
      "jsonFile": "biomarker-compliance-by-site.json",
      "drilldownLevel": 1
    },
    {
      "label": "Turnaround Time",
      "cohort": "Solid Tumors, Testing TAT",
      "jsonFile": "biomarker-compliance-tat.json",
      "drilldownLevel": 1
    },
    {
      "label": "By Cancer Type",
      "cohort": "By Cancer Type",
      "jsonFile": "biomarker-compliance-by-cancer.json",
      "drilldownLevel": 1
    },
    {
      "label": "By Provider",
      "cohort": "By Provider",
      "jsonFile": "biomarker-compliance-by-provider.json",
      "drilldownLevel": 1
    }
  ]
} 